Showing 1,761 - 1,780 results of 13,123 for search '(( significantly increased decrease ) OR ( significant ((side decrease) OR (step decrease)) ))*', query time: 0.42s Refine Results
  1. 1761
  2. 1762
  3. 1763
  4. 1764

    Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

    Published 2025
    “…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
  5. 1765
  6. 1766
  7. 1767
  8. 1768
  9. 1769
  10. 1770
  11. 1771

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  12. 1772

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 1773

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  14. 1774

    Bar charts showing the numbers of significantly differentially expressed genes for the different contrasts. by Gillian P. McHugo (8965919)

    Published 2025
    “…</sub> ≤ 0.05) with increased and decreased expression, respectively. The position on the horizontal indicates the number of days post-infection (dpi) and the colour of the bars represents the tissue. …”
  15. 1775

    RT-qPCR Primer. by Dequan Wang (6007007)

    Published 2024
    Subjects:
  16. 1776
  17. 1777
  18. 1778
  19. 1779
  20. 1780